Pfizer Inc:Pfizer Issues A Voluntary Nationwide Recall For Twelve Lots Of Chantix® (Varenicline) Tablets Due To N-Nitroso Varenicline Content.Wholesalers, Distributors With Existing Inventory Of The Lots Should Stop Use & Distribution; Quarantine The Product Immediately.Pfizer-Recalling 2 Lots Of Chantix 0.5Mg, 2 Lots Of Chantix 1 Mg Tablets, 8 Lots Of Chantix Kit Of 0.5Mg/1 Mg Tablets Due To Presence Of Nitrosamine.Believes The Benefit/Risk Profile Of Chantix Remains Positive.To Date, Pfizer Has Not Received Any Reports Of Adverse Events That Have Been Related To This Recall.As Communicated By Fda, There Is No Immediate Risk To Patients Taking Chantix.Further Company Coverage:. ((Reuters.Briefs@Thomsonreuters.Com;)).